全文获取类型
收费全文 | 11412篇 |
免费 | 876篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 99篇 |
妇产科学 | 227篇 |
基础医学 | 976篇 |
口腔科学 | 173篇 |
临床医学 | 888篇 |
内科学 | 1214篇 |
皮肤病学 | 202篇 |
神经病学 | 260篇 |
特种医学 | 862篇 |
外科学 | 1467篇 |
综合类 | 11篇 |
现状与发展 | 2篇 |
预防医学 | 315篇 |
眼科学 | 82篇 |
药学 | 480篇 |
中国医学 | 5篇 |
肿瘤学 | 4975篇 |
出版年
2024年 | 14篇 |
2023年 | 467篇 |
2022年 | 688篇 |
2021年 | 869篇 |
2020年 | 985篇 |
2019年 | 784篇 |
2018年 | 753篇 |
2017年 | 713篇 |
2016年 | 639篇 |
2015年 | 575篇 |
2014年 | 1098篇 |
2013年 | 838篇 |
2012年 | 792篇 |
2011年 | 576篇 |
2010年 | 373篇 |
2009年 | 327篇 |
2008年 | 259篇 |
2007年 | 227篇 |
2006年 | 206篇 |
2005年 | 172篇 |
2004年 | 160篇 |
2003年 | 123篇 |
2002年 | 90篇 |
2001年 | 101篇 |
2000年 | 70篇 |
1999年 | 88篇 |
1998年 | 71篇 |
1997年 | 36篇 |
1996年 | 47篇 |
1995年 | 44篇 |
1994年 | 21篇 |
1993年 | 23篇 |
1992年 | 10篇 |
1991年 | 19篇 |
1990年 | 15篇 |
1989年 | 9篇 |
1988年 | 4篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Brachytherapy》2022,21(6):726-747
PurposeIn recent years, results with mature follow-up have been reported for several Phase III trials randomizing women to receive whole breast irradiation (WBI) versus varying modalities of partial breast irradiation (PBI). It is important to recognize that these methods vary in terms of volume of breast tissue treated, dose per fraction, and duration of therapy. As such, clinical and technical guidelines may vary among the various PBI techniques.MethodsMembers of the American Brachytherapy Society with expertise in PBI performed an extensive literature review focusing on the highest quality data available for the numerous PBI options offered in the modern era. Data were evaluated for strength of evidence and published outcomes were assessed.ResultsThe majority of women enrolled on randomized trials of WBI versus PBI have been age >45 years with tumor size <3 cm, negative margins, and negative lymph nodes. The panel also concluded that PBI can be offered to selected women with estrogen receptor negative and/or Her2 amplified breast cancer, as well as ductal carcinoma in situ, and should generally be avoided in women with extensive lymphovascular space invasion.ConclusionsThis updated guideline summarizes published clinical trials of PBI methods. The panel also highlights the role of PBI for women facing special circumstances, such as history of cosmetic breast augmentation or prior breast irradiation, and discusses promising novel modalities that are currently under study, such as ultrashort and preoperative PBI. Updated consensus guidelines are also provided to inform patient selection for PBI and to characterize the strength of evidence to support varying PBI modalities. 相似文献
3.
4.
《American journal of surgery》2023,225(1):198-205
BackgroundLiver resection is commonly performed for hepatic tumors, however preoperative risk stratification remains challenging. We evaluated the performance of contemporary prediction models for short-term mortality after liver resection in patients with and without cirrhosis.MethodsThis retrospective cohort study examined National Surgical Quality Improvement Program data. We included patients who underwent liver resections from 2014 to 2019. VOCAL-Penn, MELD, MELD-Na, ALBI, and Mayo risk scores were evaluated in terms of model discrimination and calibration for 30-day post-operative mortality.ResultsA total 15,198 patients underwent liver resection, of whom 249 (1.6%) experienced 30-day post-operative mortality. The VOCAL-Penn score had the highest discrimination (area under the ROC curve [AUC] 0.74) compared to all other models. The VOCAL-Penn score similarly outperformed other models in patients with (AUC 0.70) and without (AUC 0.74) cirrhosis.ConclusionThe VOCAL-Penn score demonstrated superior predictive performance for 30-day post-operative mortality after liver resection as compared to existing clinical standards. 相似文献
5.
6.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
7.
8.
9.
10.